Expert Review of Anticancer Therapy

Papers
(The TQCC of Expert Review of Anticancer Therapy is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Triple-negative breast cancer: promising prognostic biomarkers currently in development99
TIM-3 pathway dysregulation and targeting in cancer58
TKIs in combination with immunotherapy for hepatocellular carcinoma54
CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis46
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy43
Optimal treatment in locally advanced cervical cancer32
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer31
Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies28
Pediatric relapsed acute myeloid leukemia: a systematic review28
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies27
Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy26
Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis24
The role of the microbiome in drug resistance in gastrointestinal cancers23
Is smoking an independent risk factor for developing cervical intra-epithelial neoplasia and cervical cancer? A systematic review and meta-analysis23
How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer23
Radiomics features as predictive and prognostic biomarkers in NSCLC20
Pembrolizumab for advanced cervical cancer: safety and efficacy20
Predicting pathological response to chemoradiotherapy for rectal cancer: a systematic review20
Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma19
Surgical management of intrahepatic cholangiocarcinoma18
Amivantamab for the treatment ofEGFRexon 20 insertion mutant non-small cell lung cancer18
Pembrolizumab in the first-line treatment of advanced head and neck cancer18
Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic review of the literature17
Pluripotency inducing Yamanaka factors: role in stemness and chemoresistance of liver cancer17
Immunosenescence, inflammaging, and cancer immunotherapy efficacy17
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs17
A multimodal approach to cancer-related cachexia: from theory to practice17
Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer 16
Apoferritin: a potential nanocarrier for cancer imaging and drug delivery16
Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy16
MRI radiomics in the prediction of therapeutic response to neoadjuvant therapy for locoregionally advanced rectal cancer: a systematic review15
Novel therapeutic drug strategies to tackle immune-oncological challenges faced by cancer patients during COVID-1913
Prognostic and clinicopathological value of BUB1B expression in patients with lung adenocarcinoma: a meta-analysis13
Combined endocrine and targeted therapy in luminal breast cancer13
The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance13
Clear cell sarcoma: state-of-the art and perspectives13
Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer13
Applying immune-related lncRNA pairs to construct a prognostic signature and predict the immune landscape of stomach adenocarcinoma12
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review12
Advances in systemic therapy for the first-line treatment of unresectable HCC12
Clinical management of squamous cell carcinoma of the tongue: patients not eligible for free flaps, a systematic review of the literature12
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma11
Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement11
Measurable residual disease in pediatric acute myeloid leukemia: a systematic review11
Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy11
Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives11
Development of chemotherapeutics for unresectable advanced esophageal cancer11
Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer10
Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview10
The impact of nutritional status on pancreatic cancer therapy10
The role of myeloid-derived suppressor cells in lung cancer and targeted immunotherapies10
Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence10
Chemotherapy and targeted treatments of breast sarcoma by histologic subtype10
Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors10
Colorectal cancer screening and diagnosis: omics-based technologies for development of a non-invasive blood-based method10
Ribociclib plus fulvestrant in the treatment of breast cancer10
Treatment of cervical cancer: overcoming challenges in access to brachytherapy10
Cemiplimab for locally advanced and metastatic basal cell carcinoma10
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers10
Therapeutic options in thymomas and thymic carcinomas9
What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?9
Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem9
Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma9
High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL)9
Immune checkpoint inhibitors for recurrent endometrial cancer9
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer9
The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma9
Factors associated with early lung cancer mortality: a systematic review9
Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma9
Glasdegib in newly diagnosed acute myeloid leukemia9
Brain metastases in metastatic cancer: a review of recent advances in systemic therapies9
Current androgen receptor antagonists under investigation for resistant prostate cancer9
The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma9
Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy9
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma8
Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor8
Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives8
Evaluating new treatments for anaplastic thyroid cancer8
Risk factors for the development of local recurrence in extremity soft-tissue sarcoma8
Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials8
Addressing the problem of overtreatment in breast cancer8
Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion8
Detection ofMETexon 14 skipping mutations in non-small cell lung cancer: overview and community perspective8
Tackling metastatic triple-negative breast cancer with sacituzumab govitecan8
miRNA and mRNA expression profiling reveals potential biomarkers for metastatic cutaneous melanoma8
Targeting the PI3K pathway in myeloproliferative neoplasms8
Immune checkpoint inhibition in classical hodgkin lymphoma8
Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer8
Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer8
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study8
Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer8
The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems8
Stereotactic body radiotherapy vs radiofrequency ablation for the treatment of hepatocellular carcinoma: a meta-analysis8
Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel7
Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity7
Surgical oncology in the age of multimodality therapy for cancer of the upper and lower gastrointestinal tract7
Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy7
Impact of anti-cancer therapy on disease severity and mortality in cancer patients with COVID-19: a systematic review and meta-analysis7
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis7
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma7
Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician’s guide7
The Wnt/β-catenin pathway in breast cancer therapy: a pre-clinical perspective of its targeting for clinical translation7
Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement6
Elranatamab: a new promising BispAb in multiple myeloma treatment6
Effect of primary tumor resection on survival in patients with asymptomatic unresectable metastatic colorectal cancer: a systematic review and meta-analysis6
Immunotherapy as a partner for HER2-directed therapies6
The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma6
Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma6
Overview and recent advances in the targeting of medulloblastoma cancer stem cells6
Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer6
Management of breast cancer diagnosed during pregnancy: global perspectives6
Real-world experience with trabectedin for the treatment of recurrent ovarian cancer6
A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials6
LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy6
Immunotherapy in urothelial cancer: current status and future directions6
Developments in personalized therapy for metastatic renal cell carcinoma6
Curative therapy for rectal cancer6
Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma6
Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic6
The current clinical approach to difficult-to-treat basal cell carcinomas6
Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials6
0.043782949447632